Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.
- Author:
Fu-Kang SUN
1
;
Hong-Chao HE
;
Ting-Wei SU
;
Wen-Long ZHOU
;
Xin HUANG
;
Jun DAI
;
Zhou-Jun SHEN
Author Information
1. Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Publication Type:Case Reports
- MeSH:
Adrenal Gland Neoplasms;
drug therapy;
Adult;
Female;
Humans;
Indoles;
therapeutic use;
Male;
Middle Aged;
Pheochromocytoma;
drug therapy;
Protein Kinase Inhibitors;
therapeutic use;
Pyrroles;
therapeutic use
- From:
Chinese Medical Journal
2012;125(12):2231-2234
- CountryChina
- Language:English
-
Abstract:
Sporadic malignant pheochromocytoma, a rare disease with poor prognosis, is always difficult to treat due in part to lack of effective agents. We presented three patients with advanced malignant pheochromocytoma treated by sunitinib, which indicates that sunitinib is an effective agent for this malignancy.
